THE BioMed Statistics

Total Valuation

THE BioMed has a market cap or net worth of KRW 22.66 billion. The enterprise value is 30.29 billion.

Market Cap	22.66B
Enterprise Value	30.29B

Important Dates

The last earnings date was Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

THE BioMed has 5.15 million shares outstanding. The number of shares has increased by 76.24% in one year.

Current Share Class	5.15M
Shares Outstanding	5.15M
Shares Change (YoY)	+76.24%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	0.01%
Float	3.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.88
PB Ratio	0.88
P/TBV Ratio	1.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.98
EV / Sales	6.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.60

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.83.

Current Ratio	1.89
Quick Ratio	1.09
Debt / Equity	0.83
Debt / EBITDA	n/a
Debt / FCF	-1.84
Interest Coverage	-16.09

Financial Efficiency

Return on equity (ROE) is -90.33% and return on invested capital (ROIC) is -28.23%.

Return on Equity (ROE)	-90.33%
Return on Assets (ROA)	-23.72%
Return on Invested Capital (ROIC)	-28.23%
Return on Capital Employed (ROCE)	-53.81%
Revenue Per Employee	65.35M
Profits Per Employee	-434.49M
Employee Count	71
Asset Turnover	0.08
Inventory Turnover	1.17

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.75% in the last 52 weeks. The beta is 0.83, so THE BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-68.75%
50-Day Moving Average	6,632.50
200-Day Moving Average	13,830.93
Relative Strength Index (RSI)	27.54
Average Volume (20 Days)	76,055

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, THE BioMed had revenue of KRW 4.64 billion and -30.85 billion in losses. Loss per share was -7,073.32.

Revenue	4.64B
Gross Profit	-6.02B
Operating Income	-21.97B
Pretax Income	-29.34B
Net Income	-30.85B
EBITDA	-19.88B
EBIT	-21.97B
Loss Per Share	-7,073.32

Full Income Statement

Balance Sheet

The company has 13.77 billion in cash and 21.41 billion in debt, giving a net cash position of -7.63 billion or -1,482.52 per share.

Cash & Cash Equivalents	13.77B
Total Debt	21.41B
Net Cash	-7.63B
Net Cash Per Share	-1,482.52
Equity (Book Value)	25.89B
Book Value Per Share	5,026.60
Working Capital	12.16B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.70 billion and capital expenditures -955.55 million, giving a free cash flow of -11.65 billion.

Operating Cash Flow	-10.70B
Capital Expenditures	-955.55M
Free Cash Flow	-11.65B
FCF Per Share	-2,262.60

Full Cash Flow Statement

Margins

Gross Margin	-129.73%
Operating Margin	-473.46%
Pretax Margin	-632.21%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

THE BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-76.24%
Shareholder Yield	-76.24%
Earnings Yield	-136.15%
FCF Yield	-51.42%

Stock Splits

The last stock split was on April 14, 2025. It was a reverse split with a ratio of 0.1.

Last Split Date	Apr 14, 2025
Split Type	Reverse
Split Ratio	0.1

Scores

THE BioMed has an Altman Z-Score of -3.65. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.65
Piotroski F-Score	n/a